Examining a Novel Gastrointestinal Intervention to Negate Environmental Toxicants (ENGINE)
- Conditions
- Toxicant ExposureFirefighterOccupational Exposure to Chemicals
- Interventions
- Drug: Placebo
- Registration Number
- NCT07226440
- Lead Sponsor
- University of California, San Francisco
- Brief Summary
This randomized, placebo-controlled crossover trial will test the feasibility and acceptability of using colesevelam in male firefighters with high per- and polyfluoroalkyl substances (PFAS) exposure. This trial will also explore whether colesevelam lowers blood PFAS levels and urine environmental toxicant and mold mycotoxin levels.
- Detailed Description
Firefighters experience elevated exposure to per- and polyfluoroalkyl substances (PFAS) through firefighting foams, turnout gear, and dust in fire stations. PFAS persist in the body due to their long biological half-lives, leading to bioaccumulation and raising concern for adverse effects on hormone regulation, immune function, reproduction, and cancer risk. Despite growing awareness, there are no approved treatment options to reduce PFAS levels in humans. Bile acid sequestrants, such as colesevelam, bind bile acids in the gastrointestinal tract and may interrupt enterohepatic recirculation of PFAS, thereby enhancing elimination. Observational studies and one small randomized trial suggest that bile acid sequestrants can meaningfully reduce PFAS levels. This trial will evaluate the feasibility, adherence, and acceptability of colesevelam in male firefighters with elevated PFAS, while exploring its effects on serum PFAS concentrations and urine environmental toxicant and mold mycotoxin levels.
Recruitment & Eligibility
- Status
- NOT_YET_RECRUITING
- Sex
- Male
- Target Recruitment
- 40
- Male firefighter
- California resident
- Age 18-64
- Full-time, active-duty (fire suppression and/or arson investigation) firefighter for the past 10 consecutive years
- English-speaking
- Access to a reliable internet connection
- Willing to attend 3 in-person study visits in the San Francisco Bay Area over about 6.5 months
- Willing to receive weekly text message reminders to complete online surveys
- Willing to complete a mail-based, at-home finger-prick blood test
- Willing to take 3 tablets (each tablet about the size of a multivitamin) orally twice daily for a total of 6 months
- Evaluated by study team to have an elevated risk of PFAS exposure
- Gastroparesis or other severe gastrointestinal motility disorders
- Bowel obstruction
- History of major gastrointestinal tract surgery
- Dysphagia or difficulty swallowing (due to tablet size)
- History of hypertriglyceridemia (triglycerides exceeding 500 mg/dL)
- History of hypertriglyceridemia-induced pancreatitis
- Type 1 or 2 diabetes
- History of fat-soluble vitamin deficiencies i.e., vitamins A, D, E, or K
- Phenylketonuria
- History of known bleeding/clotting disorders
- Medications or treatments that may impact the excretion of PFAS, such as activated charcoal, other bile acid sequestrants, chelation therapies, etc.
- More than one blood or plasma donation in the past 12 months and/or unalterable plans to donate blood or plasma during the study participation period
- Use of clomiphene, testosterone, human chorionic gonadotropin, anabolic steroids, anastrozole or any other substances that may impact testosterone levels in males
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Arm && Interventions
Group Intervention Description Colesevelam first Colesevelam Participants randomized to this arm will receive colesevelam, taking 3 tablets twice daily for 12 weeks, followed by a 2-week washout period, and then 12 weeks of matching placebo tablets taken on the same schedule. Both the study drug and the placebo will be provided in identical-appearing bottles to maintain blinding. Colesevelam first Placebo Participants randomized to this arm will receive colesevelam, taking 3 tablets twice daily for 12 weeks, followed by a 2-week washout period, and then 12 weeks of matching placebo tablets taken on the same schedule. Both the study drug and the placebo will be provided in identical-appearing bottles to maintain blinding. Placebo first Colesevelam Participants randomized to this arm will receive placebo tablets, taking 3 tablets twice daily for 12 weeks, followed by a 2-week washout period, and then 12 weeks of colesevelam (3 tablets twice daily). Both the study drug and the placebo will be provided in identical-appearing bottles to maintain blinding. Placebo first Placebo Participants randomized to this arm will receive placebo tablets, taking 3 tablets twice daily for 12 weeks, followed by a 2-week washout period, and then 12 weeks of colesevelam (3 tablets twice daily). Both the study drug and the placebo will be provided in identical-appearing bottles to maintain blinding.
- Primary Outcome Measures
Name Time Method Retention Enrollment to Week 27 Proportion completing all study blood draws after consent
Adherence to study drug Enrollment to Week 27 Proportion taking ≥80% of colesevelam doses
Adherence to placebo Enrollment to Week 27 Proportion taking ≥80% of placebo doses
Acceptability Week 27 Proportion endorsing "likely" or "very likely" to refer a co-worker to the study
Likability Week 27 Proportion endorsing "likely" or "very likely" to participate again
- Secondary Outcome Measures
Name Time Method Serum PFAS Levels Baseline (Week 0) to the end of each 12-week intervention period (Weeks 13 and 27) Between-period and within-person changes in serum concentrations of the National Academy of Sciences, Engineering, and Medicine (NASEM)-7 PFAS score (sum of seven PFAS analytes).
Trial Locations
- Locations (1)
UCSF Osher Center for Integrative Health
🇺🇸San Francisco, California, United States
UCSF Osher Center for Integrative Health🇺🇸San Francisco, California, United States